Elevance Health, Inc. (NYSE:ELV) Shares Bought by Childress Capital Advisors LLC

Childress Capital Advisors LLC lifted its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 12.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 776 shares of the company’s stock after buying an additional 85 shares during the quarter. Childress Capital Advisors LLC’s holdings in Elevance Health were worth $337,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in ELV. Norges Bank acquired a new position in shares of Elevance Health during the 4th quarter worth approximately $1,135,014,000. Wellington Management Group LLP raised its stake in shares of Elevance Health by 42.5% during the 4th quarter. Wellington Management Group LLP now owns 6,355,532 shares of the company’s stock worth $2,344,556,000 after buying an additional 1,893,947 shares during the period. GAMMA Investing LLC raised its stake in shares of Elevance Health by 81,726.5% during the 1st quarter. GAMMA Investing LLC now owns 1,474,514 shares of the company’s stock worth $641,355,000 after buying an additional 1,472,712 shares during the period. First Eagle Investment Management LLC raised its stake in shares of Elevance Health by 47.6% during the 4th quarter. First Eagle Investment Management LLC now owns 3,225,339 shares of the company’s stock worth $1,189,828,000 after buying an additional 1,039,612 shares during the period. Finally, Orion Portfolio Solutions LLC raised its stake in shares of Elevance Health by 6,817.8% during the 4th quarter. Orion Portfolio Solutions LLC now owns 908,795 shares of the company’s stock worth $335,254,000 after buying an additional 895,658 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ELV has been the subject of several research analyst reports. Argus set a $465.00 target price on Elevance Health in a research note on Friday, April 25th. Guggenheim reaffirmed a “buy” rating and set a $518.00 target price on shares of Elevance Health in a research note on Wednesday, April 23rd. Robert W. Baird reissued a “neutral” rating and issued a $529.00 price objective (down from $625.00) on shares of Elevance Health in a research note on Tuesday, April 15th. Baird R W downgraded Elevance Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 15th. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Elevance Health in a research note on Friday, March 28th. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $498.87.

Elevance Health Stock Down 0.6%

Shares of ELV opened at $373.71 on Monday. Elevance Health, Inc. has a 52-week low of $357.45 and a 52-week high of $567.26. The company has a market capitalization of $84.43 billion, a PE ratio of 14.58, a price-to-earnings-growth ratio of 0.95 and a beta of 0.60. The stock has a fifty day simple moving average of $398.68 and a two-hundred day simple moving average of $399.15. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.66.

Elevance Health (NYSE:ELV) last issued its earnings results on Tuesday, April 22nd. The company reported $11.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.60 by $1.37. Elevance Health had a return on equity of 18.61% and a net margin of 3.23%. The business had revenue of $48.77 billion during the quarter, compared to the consensus estimate of $46.26 billion. As a group, equities analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Tuesday, June 10th will be paid a $1.71 dividend. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.83%. The ex-dividend date of this dividend is Tuesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is presently 26.69%.

Insiders Place Their Bets

In other news, CFO Mark Kaye sold 4,588 shares of the stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $424.82, for a total transaction of $1,949,074.16. Following the completion of the transaction, the chief financial officer now directly owns 18,977 shares in the company, valued at approximately $8,061,809.14. This represents a 19.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.29% of the company’s stock.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.